Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | LIPE | Q05469 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22574535 | 0.83 | LPL (0.37) | LPLLIPGEGFRLIPEKDM4E | |
| SCHEMBL31441746 | 0.83 | LRRK2 (0.33) | LPLLIPGEGFRLIPEKDM4E | |
| SCHEMBL22585908 | 0.81 | DHODH (0.44) | LPLLIPGEGFRNPC1RAB9A | |
| SCHEMBL18342440 | 0.80 | MEN1 (0.38) | LIPEKDM4ENPC1RAB9ACXCR2 | |
| SCHEMBL14564295 | 0.80 | EGFR (0.34) | LPLLIPGEGFRCXCR2 | |
| SCHEMBL26674783 | 0.80 | PDE10A (0.37) | KDM4E | |
| SCHEMBL12077065 | 0.80 | RAB9A (0.40) | LIPEKDM4ENPC1RAB9ACXCR2 | |
| SCHEMBL30641310 | 0.78 | LIPE (0.36) | LIPECXCR2 | |
| SCHEMBL26674609 | 0.78 | LIPE (0.36) | LIPECXCR2 | |
| SCHEMBL31441577 | 0.78 | LRRK2 (0.39) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328112-B2 | Tetracyclic CDK9 kinase inhibitors | ABBVIE INC. (US) | 2016-05-03 | — | — | US | disclosed |
| WO-2015119712-A1 | TETRACYCLIC CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2015-08-13 | — | — | WO | disclosed |
| US-20150218165-A1 | TETRACYCLIC CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218165-A1 | TETRACYCLIC CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK1 | LPL 4491/4885LIPG 4067/4885EGFR 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.